These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 11798062)
41. Data-Driven Subgroup Identification in Confirmatory Clinical Trials. Bunouf P; Groc M; Dmitrienko A; Lipkovich I Ther Innov Regul Sci; 2022 Jan; 56(1):65-75. PubMed ID: 34327673 [TBL] [Abstract][Full Text] [Related]
42. Subgroup analyses and pre-specification. Unger EF Clin Trials; 2023 Aug; 20(4):338-340. PubMed ID: 36992535 [TBL] [Abstract][Full Text] [Related]
43. Tools of the trade: statistical analysis in dermatopathology articles. Flotte TJ; Duncan LM; Lerner LH; Mihm MC J Cutan Pathol; 1999 May; 26(5):265-8. PubMed ID: 10408354 [TBL] [Abstract][Full Text] [Related]
44. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Natanson C; Esposito CJ; Banks SM Crit Care Med; 1998 Dec; 26(12):1927-31. PubMed ID: 9875887 [No Abstract] [Full Text] [Related]
45. [May the lack of significance in a trial of therapeutics methods be of equal value? The result of beta-error in the planning and interpretation of clinical studies]. Tryba M Anaesthesist; 1997 Jul; 46(7):571-3. PubMed ID: 9304356 [No Abstract] [Full Text] [Related]
46. Detecting moderator effects using subgroup analyses. Wang R; Ware JH Prev Sci; 2013 Apr; 14(2):111-20. PubMed ID: 21562742 [TBL] [Abstract][Full Text] [Related]
47. Proceedings of the University of Pennsylvania 14th annual conference on statistical issues in clinical trials: Subgroup analysis in randomized clinical trials-Challenges and opportunities. Ellenberg SS; Ellenberg JH Clin Trials; 2023 Aug; 20(4):325-327. PubMed ID: 37203142 [No Abstract] [Full Text] [Related]
48. When is the story in the subgroups? Strategies for interpreting and reporting intervention effects for subgroups. Bloom HS; Michalopoulos C Prev Sci; 2013 Apr; 14(2):179-88. PubMed ID: 21279547 [TBL] [Abstract][Full Text] [Related]
49. Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke. Hemmings R; Koch A Pharm Stat; 2019 Mar; 18(2):140-144. PubMed ID: 30900391 [No Abstract] [Full Text] [Related]
51. Easy to use tools for retrieving non-published data from clinically relevant subgroups. Lima J; Jacome A Cell Rep Med; 2024 Apr; 5(4):101508. PubMed ID: 38631292 [TBL] [Abstract][Full Text] [Related]
52. [Series Epidemiology 5 Multiplicity in randomized studies II: Subgroup analyzes and intermediate evaluations]. Schulz KF; Grimes DA Z Arztl Fortbild Qualitatssich; 2007; 101(1):51-8. PubMed ID: 17458365 [No Abstract] [Full Text] [Related]
53. Key predictors of the need for a family-focused pediatric epilepsy adherence intervention. Bakula DM; Junger KW; Guilfoyle SM; Mara CA; Modi AC Epilepsia; 2022 Aug; 63(8):2120-2129. PubMed ID: 35596620 [TBL] [Abstract][Full Text] [Related]
54. Design, recruitment, and retention of African-American smokers in a pharmacokinetic study. Faseru B; Cox LS; Bronars CA; Opole I; Reed GA; Mayo MS; Ahluwalia JS; Okuyemi KS BMC Med Res Methodol; 2010 Jan; 10():6. PubMed ID: 20085641 [TBL] [Abstract][Full Text] [Related]
55. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Kravitz RL; Duan N; Braslow J Milbank Q; 2004; 82(4):661-87. PubMed ID: 15595946 [TBL] [Abstract][Full Text] [Related]
56. Evidence based medicine and justice: a framework for looking at the impact of EBM upon vulnerable or disadvantaged groups. Rogers WA J Med Ethics; 2004 Apr; 30(2):141-5. PubMed ID: 15082806 [TBL] [Abstract][Full Text] [Related]